Clayton, Australia

Garima Sharma

This inventor holds 1 USPTO granted patent. Top assignees: Monash University, Seaport Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Garima Sharma. Retrieved from https://idiyas.com/inventor/garima-sharma-nd8kctev

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Garima Sharma: Innovator in Lipid Prodrugs

Introduction

Garima Sharma is a prominent inventor based in Clayton, Australia. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of lipid prodrugs. Her innovative work focuses on improving the bioavailability of therapeutic agents, which is crucial for effective treatment.

Latest Patents

Garima Sharma holds a patent for "Lipid prodrugs of JAK inhibitors and uses thereof." This invention provides lymphatic system-directing lipid prodrugs and pharmaceutical compositions. It also includes methods for producing these prodrugs and compositions, as well as methods for treating various diseases, disorders, or conditions by administering the lipid prodrugs to patients in need.

Career Highlights

Throughout her career, Garima has worked with notable organizations such as Seaport Therapeutics, Inc. and Monash University. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of her coworkers include Joseph Bolen and Daniel Kenneth Bonner. Their collaborative efforts have further advanced the research and development of innovative pharmaceutical solutions.

Conclusion

Garima Sharma's work in lipid prodrugs exemplifies her commitment to enhancing therapeutic efficacy through innovative inventions. Her contributions are paving the way for improved treatment options in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…